[COVID-19-associated damage of the peripheral nervous system]. / COVID-19-assotsiirovannye porazheniya perifericheskoi nervnoi sistemy.

Based on the available literature data, the article discusses the prevalence of various forms of damage of the peripheral nervous system in COVID-19 and in the post-COVID period. Information about the clinical features and the course of individual cranial neuropathies, chronic dysimmune neuropathies, Guillain-Barré syndrome, drug-induced neuropathies, fine fiber neuropathy, myasthenia gravis and polyneuropathy of critical conditions was systemized in the context of coronavirus infection. SARS-CoV-2 can trigger various stages of pathogenesis, including neuroimmune ones, which cause long-term consequences of COVID-19, including those associated with the damage of the peripheral nervous system. Awareness of COVID-19-associated pathological conditions will allow assessment of the possible risks of damage of the peripheral nervous system, recognize them at early stages and develop more effective approaches for treatment.

Epilepsy and COVID-19: Management of Patients and Optimization of Antiepileptic Treatment in the Pandemic

There are as yet no data pointing to any increase in the incidence of the novel coronavirus infection (COVID-19) or a more severe course of illness in patients with epilepsy. However, considering the high prevalence of epilepsy in patients over 60 years of age, the high comorbidity of epilepsy and a whole series of somatic diseases, and the need to maintain the opportunity for constant access to antiepileptic medications and follow-up of epilepsy patients, we can expect a whole set of difficulties in the management of these patients in the conditions imposed by the COVID-19 pandemic. This article addresses the main principles of the management of epilepsy patients in the conditions of the COVID-19 pandemic: the need to follow regimes;preservation of regular and continuous taking of antiepileptic drugs, including consideration of interdrug interactions;and switching patients to i.v. forms of antiepileptic drugs where necessary.

[Epilepsy and COVID-19: patient management and optimization of antiepileptic therapy during pandemic]. / Epilepsiya i COVID-19: vedenie bol'nykh i optimizatsiya protivoepilepticheskoi terapii v usloviyakh pandemii.

There is currently no data on the increased incidence of new coronavirus infection (COVID-19) or on the more severe course of the disease in patients with epilepsy. However, given the high prevalence of epilepsy among patients after age 60, an increased burden of somatic comorbidities among people with epilepsy, as well as the need of continuous access to antiepileptic drugs (AED) and care for patients with epilepsy, there are a number of important concerns in time of regarding the management of epilepsy during COVID-19 pandemic. The article discusses the main principles of epilepsy management during the COVID-19 pandemic: the need to comply with the regime; the importance of AED adherence, taking into account drug-drug interactions; switching patients to intravenous AED forms if necessary.